Welcome, everyone, to the webcast for Ascelia Pharma AB Q1 report for 2026. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma AB and recent key events, and then we'll head into the portfolio update before moving to financials and priorities ahead.
After the presentation, we will open up for questions.
Ascelia Pharma AB. We identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. Our company is based in Malmo, Sweden, and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline.
Orviglance is a diagnostic drug that is now under FDA review, with a PDUFA date of July 3, 2026. We will spend the majority of this call talking about Orviglance.
ONCORAL is a patented tablet formulation of irinotecan, with encouraging results in Phase 1 and potential to treat a range of solid tumors. Regarding the progress of the first quarter this year, we participated in the European Society for Gastrointestinal and Abdominal Radiology (ESGAR) Conference.
There will be an oral presentation about Orviglance by Professor Dominique Geisel from the Charité Hospital in Berlin. Dr. Geisel was an investigator in our Phase 3 study, and Charité is one of the largest hospitals in Europe.
During the first quarter, our previously communicated changes in the management team took place as Anton Hansson started as our Chief Financial Officer, and Julie Waras Brogren left Ascelia Pharma; after the close of the quarter in April, we made a directed share issue and raised 20 million Swedish kronor before cost, which extends our cash runway into 2027. We're focused on our two key strategic goals: Orviglance approval and Orviglance partnering. I'm happy to say that we're on track with both of them for the approval. The milestones are the submission of the NDA on September 3rd last year, and in mid-November last year, the FDA set the due date of July 3rd, 2026. This is the date. The due date is the date where the FDA expects to make a decision on the approval of the Orviglance New Drug Application. Our NDA activities, including the interactions with the FDA, are progressing well, and we continue to be on track for the approval. The second objective is to progress Orviglance for commercialization. This is a two-pronged approach. One is to continue to advance launch readiness by ensuring manufacturing and supply chain are ready for launch, as well as working with medical experts, key opinion leaders, payers, and other key stakeholders to ensure the product will have a successful launch whenever that happens in partnership; the other track is to enter into a deal with a partner who will lead and drive the commercialization. I'm proud of the team and the progress we are making on these important milestones, and I'm optimistic for a very strong 2026 for Ascelia Pharma.
We will start the portfolio section of our presentation with Orviglance. We are very excited about Orviglance, and here's why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million addressable global market opportunity for Orviglance. Orviglance is a first-in-class product to target this and has Orphan Drug Designation from the FDA.
We have commercial scale manufacturing in place, and we have strong data from nine clinical studies, including compelling Phase 3 data. As mentioned, the Orviglance new drug application has been submitted to the FDA, and the due date is coming up in less than two months. Orviglance is an attractive asset that can help patients, and we will work with a partner to drive the commercialization. Let's talk about how Orviglance can help patients.
Cancer of the liver is a significant challenge in cancer care. Many different cancer types metastasize to the liver, meaning they start in one organ and spread to the liver. This accounts for roughly 90% of cancer in the liver in the US and Europe. The remaining 10% of cancer of the liver is when the cancer originates in the liver. The liver is often the first organ where the cancer spreads to, and also often the cause of death. That is why cancer in the liver is a major issue in cancer care, and therefore it is important to perform high-quality medical imaging to determine if the cancer has spread to the liver and how the cancer in the liver is responding to therapy or for surgical planning.
The best way to do this is with Liver MRI, and to use a Gadolinium-based contrast agent. For most patients, this works well. However, for patients with severe renal disease, they are at risk of a potentially fatal gadolinium-induced side effect known as nephrogenic systemic fibrosis. Regulatory agencies have requested a Black Box Warning on gadolinium products because of this risk.
It is exactly these patients that we aim to help with. Orviglance provides high quality imaging, and because it is based on Manganese, there are none of the gadolinium-associated risks.
This unmet medical need translates into a global addressable market opportunity of $800 million on an annual basis. The US market is almost half of this, and therefore we have prioritized the US market. Ascelia will work with partners to drive the commercialization of Orviglance.
Let's talk a bit more about the key metrics for the US market based on real-world data.
There are about 100,000 relevant procedures in the Orviglance target population every year in the US because of their disease and comorbidities. These patients are mostly treated at the major medical centers, and 75% of these imaging procedures are made at the 400 largest Medicare accounts. Based on market research, pricing benchmarks for high-value diagnostic drugs can range from $3,000 to $4,500 per dose. Orviglance is addressing a well-recognized medical need.
As mentioned previously, Orviglance is targeting patients with severe renal disease because of the gadolinium associated risks. The medical community is well aware of this, and our market research demonstrates that more than 90% of healthcare professionals are concerned about gadolinium-associated risk, and a number of them have also experienced nephrogenic systemic fibrosis in patients. Orviglance is targeting patients with severe renal impairment, which is the highest-risk population defined by the black box warning.
With every gadolinium injection, there is also a deposition of gadolinium in tissue in the body, including in the brain. Every gadolinium injection, there is also a deposition of gadolinium in tissues throughout the body, including in the brain. The consequences of this continue to be evaluated in the scientific community, including long-term effects of the deposition.
Another issue is the gadolinium accumulation in our water supply. After the gadolinium contrast injection, the gadolinium is excreted in the urine, which goes into our sewer system, and filtration systems are unable to remove the gadolinium. And as a consequence, gadolinium content in drinking water has increased over the last decades. These are important drivers for the future of MRI.
Ascelia Pharma is leading the charge, with Orviglance being based on manganese and under FDA review. If and when approved, it will be the only manganese product on the market. The gadolinium manufacturers recognized the gadolinium challenges. GE HealthCare is developing an injectable manganese agent. They have completed a Phase 1 study and have recently started a Phase 2/3 study.
We consider this a positive development with increased focus on manganese agents, and based on what we know, these two products are complementary to each other.
The other gadolinium manufacturers have developed gadolinium products with lower doses of gadolinium to reduce the impact. These underlying developments support the need for products such as Orviglance, and we believe the timing for bringing Orviglance to the market is good.
We have a clearly stated strategic goal of entering into a partnership with a company that will lead the commercialization of Orviglance. Orviglance represents an attractive commercial opportunity, and we are making good progress in our partnering dialogues.
Now we'll transition to the scientific and regulatory section. And Andreas, please go ahead.